Navigation Links
Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain
Date:5/18/2009

Post-Treatment Segment of Elagolix Petal Study Confirms Previous Positive Findings on Efficacy and Safety

Neurocrine to Present These Additional Study Results at Deutsche Bank 34th Annual Healthcare Conference Today at 5:05pm Eastern Time

SAN DIEGO, May 18 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced additional positive safety and efficacy results from its Phase IIb clinical trial known as the Petal Study (603 study) using its proprietary, orally-active non-peptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis. The Petal Study enrolled 252 patients, with a confirmed diagnosis of endometriosis, into three treatment groups; elagolix 150 mg once daily, elagolix 75 mg twice daily, or depo-subQ provera 104(TM) (DMPA) for six months of treatment followed by six months of no treatment. Database lock and unblinding of the full 48 week data set has provided more insight on the clinical benefits and safety profile of elagolix for the treatment of pain associated with endometriosis.

"As expected, elagolix did not induce significant bone loss over the six-month follow up phase of the Petal Study," said Chris O'Brien, MD, Neurocrine's Chief Medical Officer. "Additionally, we are seeing for the first time an oral GnRH antagonist with a rapid and sustained symptom reduction during treatment that also provides a statistically and clinically significant improvement in symptoms which persists after discontinuation of therapy. These are intriguing results and raise the possibility that elagolix treatment may have a disease modifying effect."

Key findings include the following:

Bone Safety: As previously reported, the primary endpoint of the Petal Study, impact on bone mineral density (BMD), was
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2009 Financial Results
2. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2008 Results
3. Webcast Alert: Neurocrine Announces 1Q08 Financial Results
4. Neurocrine Announces Closing of $109 Million Sale and Leaseback Agreement for its Real Estate Assets
5. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
6. Coalition for Pulmonary Fibrosis Announces Awards and Activities at ATS International Conference
7. GNAX/AtlantaNAP Announces Newest Client, Health Information Designs
8. AstraZeneca Announces TOPROL-XL(R) (Metoprolol Succinate) is Now Available
9. AMR Research Announces Final Agenda for Sold-Out Supply Chain Executive Conference
10. International Student Insurance Announces Website Redesign
11. Light Sciences Oncology Announces Results of Study on Immunotherapeutic Mechanism of Aptocine(TM), a Novel Light-Activated Drug Therapy for Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015 The American College ... events in June. They will hold a webinar on ... a two-day class on Classical Chinese Medicine. , Webinar ... Dr. Steve Given, the Dean of Clinical Education, will ... new First Professional Doctorate program. ACTCM is currently developing ...
(Date:5/22/2015)... 2015 Hundreds of federal Xarelto ... individuals who allegedly experienced serious internal bleeding and ... move forward in the U.S. District Court, Eastern ... dated May 4, 2015, the Court has established ... stored information. Among other things, the Order sets ...
(Date:5/22/2015)... UK (PRWEB) May 22, 2015 ... leading treatment option for chronic obstructive pulmonary disorder ... GlaxoSmithKline plc and AstraZeneca plc as well as ... market share and position. But will market payers, ... the already well-entrenched products to completely new ones? ...
(Date:5/22/2015)... DC (PRWEB) May 22, 2015 Family, ... University Hospital’s world-renowned surgical oncologist, Dr. LaSalle D. Leffall, ... , The luncheon began after Grand Rounds in the ... Leffall, waited anxiously outside the auditorium, trying to keep ... him, but if he sees me, he’ll know something ...
(Date:5/22/2015)... R.I. (PRWEB) May 22, 2015 Memorial Day ... Amica Insurance is offering some tips to help ... Safety Council, there will be 383 traffic fatalities this Memorial ... from the National Highway Traffic Safety Association: , ... in the vehicle is wearing a seatbelt, whether they’re driving ...
Breaking Medicine News(10 mins):Health News:ACTCM Announces Upcoming June Events 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 3Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 4Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2Health News:Amica Has 4 Road Safety Tips for Memorial Day Weekend 2
... By Steven Reinberg HealthDay Reporter , MONDAY, ... of eggs potentially tainted by salmonella, the head of the ... see some additional sort of sub-recalls over the next couple ... network of distribution of these eggs that are contaminated," agency ...
... researchers are reporting on the discovery of a bug with ... the researchers questioning whether they could believe their own eyes. ... demonstration of truly bifocal lenses in the extant animal kingdom," ... the premier life-science journal, Current Biology . The ...
... short-term and long-term costs of prostate cancer care vary ... receives. Published early online in Cancer , a ... finds that treatments that may be less expensive in ... men with early stage prostate cancer, various treatments are ...
... using time-lapse microscopy, researchers at the University of California, ... for Cancer Research have discovered an unusual property of ... sexually reproducing organisms. The discovery of an "inside ... each other may shed light on mistakes made in ...
... French . , Montreal, August 20, 2010 Sexual ... become the subject of a new book by a University ... (Wiley), is the first volume of its kind to provide ... as well as treatment options for offenders. The book ...
... which will study the effect of hydrogen sulfide (H 2 S ... won a research grant of 140,000 over three years from the ... and, when in balance with other chemical compounds that occur naturally ... team investigated the role of H 2 S in toxic shock, ...
Cached Medicine News:Health News:FDA Chief Says More Egg Recalls Possible 2Health News:FDA Chief Says More Egg Recalls Possible 3Health News:FDA Chief Says More Egg Recalls Possible 4Health News:Researchers gain focus on a bug with bifocals 2Health News:Cost of prostate cancer care varies with initial treatment choice 2Health News:Study of cell division sheds light on special mechanism in egg cells 2Health News:Female sexual offenders: Unrecognized and underreported 2Health News:Grant for 'rotten eggs' anti-inflammatory research 2
(Date:5/22/2015)... , May 22, 2015  RegeneRx Biopharmaceuticals, Inc. ... a peer-reviewed publication of the results of the ... (RegeneRx,s preservative-free eye drops) for the treatment of ... environment (CAE ® ) model.  The exploratory study ... which were previously disseminated by the Company in ...
(Date:5/22/2015)... 22, 2015   InspireMD, Inc. (NYSE MKT: NSPR) ... systems ("EPS"), today announced that its CGuard TM Embolic ... investigator Prof. Piotr Musialek , at the EuroPCR ... France . PARADIGM, an investigator-initiated P ... A roti D revascularization I n symptomatic and ...
(Date:5/22/2015)... , May 22, 2015 ... clinical research unit with a worldwide reputation for ... its frequent publications in peer reviewed medical journals. ... stakeholders and regulators in discussions about rules for ...      (Logo: http://photos.prnewswire.com/prnh/20150522/745125) , Clinical ...
Breaking Medicine Technology:Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: